Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Jul. 31, 2019 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
| Patent and licensing costs | $ 742,918 | $ 842,325 | |
| Research and development costs | $ 820,906 | $ 40,703 | |
| Concentration of risk, percentage | 10.00% | 10.00% | |
| Deferred setup and organization costs, amortization period | 180 months | ||
| Unrecognized tax benefits | |||
| Collaboration Agreement [Member] | |||
| Research and development costs | 87,471 | ||
| Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member] | |||
| Collaboration agreement description | Effective as of July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with GEIS to carry out a clinical trial entitled "Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma". The Company estimates that this clinical trial will be completed and results will be published by June 2023. | ||
| Research and development costs | $ 87,471 | ||
| Concentration of risk, percentage | 10.70% | ||
| X | ||||||||||
- Definition Collaboration agreement description. No definition available.
|
| X | ||||||||||
- Definition The amortization period for recovery of the deferred set-up and organization costs for Federal tax purposes. No definition available.
|
| X | ||||||||||
- Definition Patent and licensing costs. No definition available.
|
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|